On the other hand, the early steps of the anti-tumor T cell response, namely activation and secretion of IL-2, seem to be mostly preserved by metformin treatment, suggesting that the potential suppressive effects of metformin could be more relevant in modulating the effector stage rather than the initial antigen presentation, T cell activation and IL-2 induced expansion in the lymph nodes. This evidence concerns the gene IL2 and neoplasm.